{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    8,
    9,
    10,
    14,
    15,
    30,
    40,
    42,
    43,
    44,
    48,
    50,
    51,
    53,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "OS Analysis Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1, 6.4.1.1, 6.10",
        "sectionTitle": "Statistical Analysis Sections",
        "description": "Clarification of descriptive and optional nature of subsequent overall survival analyses"
      },
      {
        "id": "ref_2",
        "name": "Safety Plan Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.1",
        "sectionTitle": "Atezolizumab Risks",
        "description": "Reference to Severe Cutaneous Adverse Reactions added as a risk"
      },
      {
        "id": "ref_3",
        "name": "COVID-19 Considerations",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.6.3",
        "sectionTitle": "COVID-19 Considerations",
        "description": "New section added to describe COVID-19-related risks"
      },
      {
        "id": "ref_4",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Updated criteria regarding severe infection and investigator opinion"
      },
      {
        "id": "ref_5",
        "name": "Safety Plan COVID Update",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Safety Plan",
        "description": "Inclusion of COVID-19 risk language regarding active infection"
      },
      {
        "id": "ref_6",
        "name": "Tumor Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.5",
        "sectionTitle": "Tumor and Response Evaluations",
        "description": "Reference for tumor assessment intervals"
      },
      {
        "id": "ref_7",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference for timing of study assessments and procedures"
      },
      {
        "id": "ref_8",
        "name": "Study Design Schema",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Schema",
        "description": "Visual overview of the study design"
      },
      {
        "id": "ref_9",
        "name": "AASLD Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 13",
        "sectionTitle": "Algorithm for Investigation of Small Nodules",
        "description": "Criteria for HCC diagnosis in cirrhotic patients"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Caution should be used in patients who have previously experienced a severe or life-threatening atezolizumab skin adverse reaction",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Appendix 8",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Substantive new information appears in italics.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale for Amendment",
        "pageNumber": 2
      },
      {
        "id": "annot_3",
        "text": "Patients may be transfused to meet this criterion (Hemoglobin >= 90 g/L).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.1.1 Inclusion Criteria",
        "pageNumber": 52
      },
      {
        "id": "annot_4",
        "text": "Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 5 minutes between dosing.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 2: Study Treatment Regimens",
        "pageNumber": 60
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-10-18",
        "description": "Initial Protocol",
        "amendmentNumber": "Original"
      },
      {
        "id": "ver_2",
        "versionNumber": "6",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-02-01",
        "description": "Primary alignment with Atezolizumab Investigatorâ€™s Brochure Version 17 and COVID-19 updates",
        "amendmentNumber": "Amendment 6"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 4,
      "versionCount": 2
    }
  }
}